GCIA
BBIO icon

Gabelli & Co Investment Advisers’s BridgeBio Pharma BBIO Stock Holding History

Gabelli & Co Investment Advisers’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$335K Hold
4,500
– – 0.05% 217
2026
Q1 		$334K Hold
4,500
– – 0.05% 198
2025
Q4 		$344K Hold
4,500
– – 0.05% 181
2025
Q3 		$234K Buy
+4,500
New +$219K 0.04% 205

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Gabelli & Co Investment Advisers's BBIO Position: Q2 2026 in Review

Gabelli & Co Investment Advisers held its BridgeBio Pharma (BBIO) position steady in Q2 2026 at 4,500 shares worth $335K. The position accounts for 0.05% of the portfolio, ranked #217.

Gabelli & Co Investment Advisers first reported a position in BBIO in Q3 2025 and has held it in 4 quarters since. The position peaked at $344K in Q4 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Gabelli & Co Investment Advisers held 4,500 shares of BridgeBio Pharma worth $335K as of Q2 2026.
  • Gabelli & Co Investment Advisers left its BridgeBio Pharma share count unchanged in Q2 2026.
  • BridgeBio Pharma made up 0.05% of Gabelli & Co Investment Advisers's portfolio in Q2 2026, its #217 holding.
  • Gabelli & Co Investment Advisers first reported a position in BridgeBio Pharma in Q3 2025 and has held it in 4 quarters since.
  • Gabelli & Co Investment Advisers's BridgeBio Pharma position peaked at $344K in Q4 2025.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Gabelli & Co Investment Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.